

**Press Release****29 June 2018****Change in the number of shares and votes in Nuevolution AB**

Stockholm, 29 June 2018 – Nuevolution AB today announced that the number of shares and votes in the company amounts to 49,524,903 as per 29 June 2018.

As a result of a directed issue executed on 24 May, the number of shares and votes increased with 6,666,667, from 42,858,236 to 49,524,903. Nuevolution AB does not hold any own shares.

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 3913 0902

Email: ahg@nuevolution.com

Henrik Damkjær Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com**Information about Nuevolution AB (publ)**

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution's internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information is such information that Nuevolution is obliged to make public pursuant to the Financial Instruments Trading Act. The information was sent for publication, through the agency of the contact persons set out above, on 29 June 2018 at 08:00 CEST.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com

